Rapid Micro Rejects Takeover Deal, Adopts Poison Pill To Thwart Investor


20-Year Pro Trader Reveals His "MoneyLine"

Ditch your indicators and use the "MoneyLine". A simple line tells you when to buy and sell without the guesswork. It’s a line on a chart that’s helped Nic Chahine win 83% of his options buys. Here's how he does it.


  • Rapid Micro Biosystems Inc (NASDAQ: RPID) has initiated a review of strategic alternatives and has retained Morgan Stanley & Co. LLC as its financial advisor and Goodwin Procter LLP as its legal advisor to assist in its review.
  • In addition, the company said it rejected an unsolicited non-binding proposal of $5/share from Kennedy Lewis Investment Management LLC, citing the proposal as 'inadequate.'
  • Q2 sales declined to $3.9 million from $5.7 million a year ago, attributable to fewer placements of Growth Direct systems and lower validation revenue due to a few customer-related delays.
  • Analysts estimates sales of $4.57 million.
  • Cash, cash equivalents, and investments were $166.9 million.
  • The company expects FY22 sales of at least $17.0 million, assuming a placement of three to five systems in 2H of 2022, with most or all of those placements made in the fourth quarter. 
  • The company's lowered guidance reflects expectations for fewer systems placements and macro-economic uncertainty.
  • Rapid Micro Biosystems will cut 20% of its workforce as an organizational restructuring plan to right-size its cost structure based on its lowered 2022 outlook.
  • The restructuring plan will result in approximately $8.0 - $9.0 million in annualized cost savings by Q1 of 2023. It expects to incur restructuring charges of approximately $1.5 million in Q3.
  • Price Action: RPID shares are down 7.67% at $3.90 during the market session on the last check Friday.

20-Year Pro Trader Reveals His "MoneyLine"

Ditch your indicators and use the "MoneyLine". A simple line tells you when to buy and sell without the guesswork. It’s a line on a chart that’s helped Nic Chahine win 83% of his options buys. Here's how he does it.


ENTER TO WIN $500 IN STOCK OR CRYPTO

Enter your email and you'll also get Benzinga's ultimate morning update AND a free $30 gift card and more!

Posted In: BiotechEarningsM&ANewsPenny StocksHealth CareMoversTrading IdeasGeneralBriefs